The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A new strategy to understand how HIV infects women: identification of a window of vulnerability during the menstrual cycle
Open accessAbstract
Introduction Although 85% of new HIV cases are due to sexual transmission from men to women, little attention is being paid to the immune system in the female reproductive tract (FRT), and to how it meets the conflicting challenges of protecting from pathogens and permitting procreation. As a new approach we have tried to envision how HIV evades FRT mucosal immune protection and have been led to the unexpected conclusion that in a normal menstrual cycle, there is a window of vulnerability (7–10 days following ovulation) in which the potential for viral infectivity in the FRT is enhanced. During that period, aspects of the innate, humoral, and cell-mediated immune systems are suppressed by sex hormones to optimize conditions for procreation. Suppression occurs in the upper (Fallopian tubes, uterus, endocervix) and lower (ectocervix and vagina) FRT, and coincides with the recruitment of potentially infectable cells and upregulation of coreceptors essential for viral uptake. Implications of these findings are that the entire FRT is a potential target for HIV infection, immune cells and antibodies in blood are not surrogate markers for immune protection in the FRT, and immune protection against HIV will require an understanding of the hormone-induced regulation of humoral, cell-mediated, and innate immune systems throughout the FRT. The need to understand the interplay between the immune and endocrine systems in the human female reproductive tract Despite unprecedented efforts by scientists worldwide, the solution to the ever-growing HIV/AIDS crisis remains elusive. HIV/AIDS is unique in modern human history in its rapid spread, its extent, and the depth of its impact. Since the first AIDS case was diagnosed in 1981, the world has struggled to come to grips with its extraordinary toll. Approaching 25 million deaths worldwide with an additional 33.2 million (of which 15.4 million are women) estimated to be infected worldwide, HIV/AIDS will soon be the world's worst pandemic [1]. With the recent failures of the Diaphragm trial, the Merck vaccine trial, and the Microbicide gel trial [2–6] along with recognition that for each person treated with antiretrovirals, six are newly infected with HIV [7], it remains unclear when safe and effective protection will become available. The failure of apparently promising approaches highlights the urgency to better understand how to prevent HIV transmission in women. Women are approximately twice as likely to contract HIV infection from men as men are from women during vaginal intercourse [8]. Each year brings an increase in the percentage of women infected with HIV. In particular, women and girls make up about 57% of all people infected with HIV in sub-Saharan Africa, where a striking 76% of those with HIV in the 15–24 year age group are female [9]. In the United States, the proportion of AIDS cases reported among women increased from 7% in 1985 to 28% in 2005 [1,8]. Our interest in the reproductive tract immune system over the past 25 years has been refocused by the human tragedy of AIDS. As 80% of new HIV infections are due to heterosexual transmission, our efforts are concentrated on mucosal protection [10]. What is difficult to reconcile is that whereas the number of women infected has reached 20 million, the estimated rate of HIV transmission per coital act is low, 1: 122 to 1: 1000 [11,12]. These findings suggest that, while transmission is related to the viral load [13], exposure time following seroconversion [14] and pre-existence of other sexually transmitted infections (STIs), there exists within the FRT a window of vulnerability through which HIV, and probably other STI, can gain access to the body. Lacking in many studies is an appreciation of the reproductive process and the complexity of the FRT. To understand the immunological response of the FRT to pathogenic challenge, one must first appreciate that, unlike other mucosal immune sites, the FRT has evolved to complement the reproductive events occurring each month. The FRT consists of five distinct anatomical sites (Fallopian tubes, uterus, endocervix, ectocervix, and vagina), which function separately yet in coordinated fashion. Each site is controlled by estradiol and progesterone. Extensive studies [15] have defined how these functions are synchronized to optimize the chances for successful fertilization, implantation, and pregnancy. Our working hypothesis Critical to the reproductive process is the ability of the immune system to distinguish between semiallogeneic sperm, an allogeneic fetal placental unit, and potential pathogens. Herein lies the problem of understanding the realities of heterosexual transmission of HIV from men to women at FRT mucosal surfaces. As have others, we have designed our studies to define the components of the immune system present in the FRT, how these protect against pathogens, and how they are controlled by sex hormones [16–18]. Recently, we challenged ourselves to understand h
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda.
Wawer, M. J., Gray, R. H., Sewankambo, N. K., Serwadda, D., Li, X., Laeyendecker, O., Kiwanuka, N., Kigozi, G., Kiddugavu, M., Lutalo, T., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/429411 · Cited by 1,258
Kunz, G., Beil, D., Deininger, H., Wildt, L., & Leyendecker, G. (1996) · Human Reproduction · doi:10.1093/humrep/11.3.627 · Cited by 408
Sato, K., Kawasaki, H., Nagayama, H., Enomoto, M., Morimoto, C., Tadokoro, K., Juji, T., & Takahashi, T. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2285 · Cited by 152
Cited by
Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors
Gonçalves, B., Ferreira, C., Alves, C. T., Henriques, M., Azeredo, J., & Silva, S. (2016) · Critical Reviews in Microbiology · doi:10.3109/1040841x.2015.1091805 · Cited by 669
The role of sex hormones in immune protection of the female reproductive tract
Wira, C. R., Rodriguez-Garcia, M., & Patel, M. V. (2015) · Nature Reviews Immunology · doi:10.1038/nri3819 · Cited by 444
Self-citationHormonal Contraception and the Risk of HIV Acquisition: An Individual Participant Data Meta-analysis
Morrison, C. S., Chen, P.-L., Kwok, C., Baeten, J. M., Brown, J., Crook, A. M., Van Damme, L., Delany-Moretlwe, S., Francis, S. C., Friedland, B. A., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001778 · Cited by 355
Women and HIV in Sub-Saharan Africa
Ramjee, G., & Daniels, B. (2013) · AIDS Research and Therapy · doi:10.1186/1742-6405-10-30 · Cited by 341
Wessels, J. M., Felker, A. M., Dupont, H. A., & Kaushic, C. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.035147 · Cited by 102
“Collectively, these results help illuminate the possible mechanisms by which progesterone might modulate immunity in the FGT and relate to HIV-1 susceptibility, which is greater in women in the progesterone-high luteal phase of the menstrual cycle (Saba et al., 2013; Wira and Fahey, 2008).”
Metadata
- Authors
- Wira, C. R., & Fahey, J. V.
- Venue
- AIDS
- Published
- 2008-10-01
- Volume
- 22
- Issue
- 15
- Pages
- 1909-1917
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2057023184
- Cited by
- 245
- References
- 3
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.